Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ANAGASTRA 40 mg COMPRIMIDOS GASTRORRESISTENTES - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/ANAGASTRA 40 mg COMPRIMIDOS GASTRORRESISTENTES

Approved

STANDARD

ANAGASTRA 40 mg COMPRIMIDOS GASTRORRESISTENTES

Takeda Belgium🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Nov 12, 2025
Approval ID: cba9fe1836c96e76
Company: Takeda Belgium
Type: Standard

Approval Details

Approval Id: cba9fe1836c96e76
Drug Cima Aemps Name: ANAGASTRA 40 mg COMPRIMIDOS GASTRORRESISTENTES
Register Number: BE318272IP2
Holder Company Name: Takeda Belgium
Marketing Company Name: Difarmed S.L.U.
Authorization Date: 2025-11-12
Dosage Form: COMPRIMIDO GASTRORRESISTENTE
Dose: 40 mg pantoprazol
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: No
Company Name: Takeda Belgium

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Nov 12, 2025

Approval ID

cba9fe1836c96e76

Type

Standard

Back to CIMA-AEMPS Approvals